CELL REP 润色咨询

Cell Reports

出版年份：暂无数据 年文章数：10575 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：2.2% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2214992, encodeId=23d1221499279, content=with editor都12天了都还没更新状态，正常不呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=280, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Mon Jul 15 10:10:53 CST 2024, time=2024-07-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278979, encodeId=b5c622e8979b4, content=送审后审稿人说图像可能有问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f158275089, createdName=ms9000000864190369, createdTime=Wed Aug 27 21:46:50 CST 2025, time=2025-08-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2268654, encodeId=fe9e22686547a, content=审稿严谨，但编辑倾向维护审稿人权威<br>​​投稿​​1周，编辑初审通过，送外审（3名审稿人）<br>​​一审结果​​3个月，​​2人支持修订，1人拒稿​​<br>​​申诉2周，提供领域内权威文献证明K→R突变的普适性，编辑同意转大修<br>​​返修提交​​1个月多月<br>​​二审结果​​2个月，Reviewer 1/2无意见，Reviewer 3仍拒稿，编辑最终拒稿，太折腾了悲催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Mon Jun 09 23:23:33 CST 2025, time=2025-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2252190, encodeId=eb1e225219097, content=请问是否需要那个作者确认？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70d82534981, createdName=1250caacm11暂无昵称, createdTime=Sun Feb 16 14:42:55 CST 2025, time=2025-02-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2226589, encodeId=ee43222658985, content=请问一下Cell Rep跟JECCR，选哪一个好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c4c05433377, createdName=ms4000000962704650, createdTime=Thu Sep 19 15:39:00 CST 2024, time=2024-09-19, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=296, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2240785, encodeId=82a82240e85ca, content=即时影响因子5.83，为什么一直在降呢，上边的文章质量都很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Wed Dec 04 15:25:04 CST 2024, time=2024-12-04, status=1, ipAttribution=北京)]
    2024-07-15 沧海医僧笑 来自重庆

    with editor都12天了都还没更新状态，正常不呢

    6

    展开6条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2214992, encodeId=23d1221499279, content=with editor都12天了都还没更新状态，正常不呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=280, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Mon Jul 15 10:10:53 CST 2024, time=2024-07-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278979, encodeId=b5c622e8979b4, content=送审后审稿人说图像可能有问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f158275089, createdName=ms9000000864190369, createdTime=Wed Aug 27 21:46:50 CST 2025, time=2025-08-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2268654, encodeId=fe9e22686547a, content=审稿严谨，但编辑倾向维护审稿人权威<br>​​投稿​​1周，编辑初审通过，送外审（3名审稿人）<br>​​一审结果​​3个月，​​2人支持修订，1人拒稿​​<br>​​申诉2周，提供领域内权威文献证明K→R突变的普适性，编辑同意转大修<br>​​返修提交​​1个月多月<br>​​二审结果​​2个月，Reviewer 1/2无意见，Reviewer 3仍拒稿，编辑最终拒稿，太折腾了悲催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Mon Jun 09 23:23:33 CST 2025, time=2025-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2252190, encodeId=eb1e225219097, content=请问是否需要那个作者确认？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70d82534981, createdName=1250caacm11暂无昵称, createdTime=Sun Feb 16 14:42:55 CST 2025, time=2025-02-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2226589, encodeId=ee43222658985, content=请问一下Cell Rep跟JECCR，选哪一个好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c4c05433377, createdName=ms4000000962704650, createdTime=Thu Sep 19 15:39:00 CST 2024, time=2024-09-19, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=296, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2240785, encodeId=82a82240e85ca, content=即时影响因子5.83，为什么一直在降呢，上边的文章质量都很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Wed Dec 04 15:25:04 CST 2024, time=2024-12-04, status=1, ipAttribution=北京)]
    2019-12-17 147d7137m03(暂无昵称)

    审稿速度:2.0 | 投稿命中率:25.0
    经验分享：allreviewcompleted等待编辑决定煎熬中

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2214992, encodeId=23d1221499279, content=with editor都12天了都还没更新状态，正常不呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=280, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Mon Jul 15 10:10:53 CST 2024, time=2024-07-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278979, encodeId=b5c622e8979b4, content=送审后审稿人说图像可能有问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f158275089, createdName=ms9000000864190369, createdTime=Wed Aug 27 21:46:50 CST 2025, time=2025-08-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2268654, encodeId=fe9e22686547a, content=审稿严谨，但编辑倾向维护审稿人权威<br>​​投稿​​1周，编辑初审通过，送外审（3名审稿人）<br>​​一审结果​​3个月，​​2人支持修订，1人拒稿​​<br>​​申诉2周，提供领域内权威文献证明K→R突变的普适性，编辑同意转大修<br>​​返修提交​​1个月多月<br>​​二审结果​​2个月，Reviewer 1/2无意见，Reviewer 3仍拒稿，编辑最终拒稿，太折腾了悲催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Mon Jun 09 23:23:33 CST 2025, time=2025-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2252190, encodeId=eb1e225219097, content=请问是否需要那个作者确认？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70d82534981, createdName=1250caacm11暂无昵称, createdTime=Sun Feb 16 14:42:55 CST 2025, time=2025-02-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2226589, encodeId=ee43222658985, content=请问一下Cell Rep跟JECCR，选哪一个好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c4c05433377, createdName=ms4000000962704650, createdTime=Thu Sep 19 15:39:00 CST 2024, time=2024-09-19, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=296, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2240785, encodeId=82a82240e85ca, content=即时影响因子5.83，为什么一直在降呢，上边的文章质量都很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Wed Dec 04 15:25:04 CST 2024, time=2024-12-04, status=1, ipAttribution=北京)]
    2025-08-27 ms9000000864190369 来自湖北省

    送审后审稿人说图像可能有问题

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2214992, encodeId=23d1221499279, content=with editor都12天了都还没更新状态，正常不呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=280, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Mon Jul 15 10:10:53 CST 2024, time=2024-07-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278979, encodeId=b5c622e8979b4, content=送审后审稿人说图像可能有问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f158275089, createdName=ms9000000864190369, createdTime=Wed Aug 27 21:46:50 CST 2025, time=2025-08-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2268654, encodeId=fe9e22686547a, content=审稿严谨，但编辑倾向维护审稿人权威<br>​​投稿​​1周，编辑初审通过，送外审（3名审稿人）<br>​​一审结果​​3个月，​​2人支持修订，1人拒稿​​<br>​​申诉2周，提供领域内权威文献证明K→R突变的普适性，编辑同意转大修<br>​​返修提交​​1个月多月<br>​​二审结果​​2个月，Reviewer 1/2无意见，Reviewer 3仍拒稿，编辑最终拒稿，太折腾了悲催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Mon Jun 09 23:23:33 CST 2025, time=2025-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2252190, encodeId=eb1e225219097, content=请问是否需要那个作者确认？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70d82534981, createdName=1250caacm11暂无昵称, createdTime=Sun Feb 16 14:42:55 CST 2025, time=2025-02-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2226589, encodeId=ee43222658985, content=请问一下Cell Rep跟JECCR，选哪一个好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c4c05433377, createdName=ms4000000962704650, createdTime=Thu Sep 19 15:39:00 CST 2024, time=2024-09-19, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=296, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2240785, encodeId=82a82240e85ca, content=即时影响因子5.83，为什么一直在降呢，上边的文章质量都很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Wed Dec 04 15:25:04 CST 2024, time=2024-12-04, status=1, ipAttribution=北京)]
    2025-06-09 ms6000002977722155 来自上海

    审稿严谨，但编辑倾向维护审稿人权威
    ​​投稿​​1周，编辑初审通过，送外审（3名审稿人）
    ​​一审结果​​3个月，​​2人支持修订，1人拒稿​​
    ​​申诉2周，提供领域内权威文献证明K→R突变的普适性，编辑同意转大修
    ​​返修提交​​1个月多月
    ​​二审结果​​2个月，Reviewer 1/2无意见，Reviewer 3仍拒稿，编辑最终拒稿，太折腾了悲催

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2214992, encodeId=23d1221499279, content=with editor都12天了都还没更新状态，正常不呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=280, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Mon Jul 15 10:10:53 CST 2024, time=2024-07-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278979, encodeId=b5c622e8979b4, content=送审后审稿人说图像可能有问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f158275089, createdName=ms9000000864190369, createdTime=Wed Aug 27 21:46:50 CST 2025, time=2025-08-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2268654, encodeId=fe9e22686547a, content=审稿严谨，但编辑倾向维护审稿人权威<br>​​投稿​​1周，编辑初审通过，送外审（3名审稿人）<br>​​一审结果​​3个月，​​2人支持修订，1人拒稿​​<br>​​申诉2周，提供领域内权威文献证明K→R突变的普适性，编辑同意转大修<br>​​返修提交​​1个月多月<br>​​二审结果​​2个月，Reviewer 1/2无意见，Reviewer 3仍拒稿，编辑最终拒稿，太折腾了悲催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Mon Jun 09 23:23:33 CST 2025, time=2025-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2252190, encodeId=eb1e225219097, content=请问是否需要那个作者确认？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70d82534981, createdName=1250caacm11暂无昵称, createdTime=Sun Feb 16 14:42:55 CST 2025, time=2025-02-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2226589, encodeId=ee43222658985, content=请问一下Cell Rep跟JECCR，选哪一个好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c4c05433377, createdName=ms4000000962704650, createdTime=Thu Sep 19 15:39:00 CST 2024, time=2024-09-19, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=296, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2240785, encodeId=82a82240e85ca, content=即时影响因子5.83，为什么一直在降呢，上边的文章质量都很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Wed Dec 04 15:25:04 CST 2024, time=2024-12-04, status=1, ipAttribution=北京)]
    2025-02-16 1250caacm11暂无昵称 来自山东省

    请问是否需要那个作者确认？

    2

    展开2条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2214992, encodeId=23d1221499279, content=with editor都12天了都还没更新状态，正常不呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=280, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Mon Jul 15 10:10:53 CST 2024, time=2024-07-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278979, encodeId=b5c622e8979b4, content=送审后审稿人说图像可能有问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f158275089, createdName=ms9000000864190369, createdTime=Wed Aug 27 21:46:50 CST 2025, time=2025-08-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2268654, encodeId=fe9e22686547a, content=审稿严谨，但编辑倾向维护审稿人权威<br>​​投稿​​1周，编辑初审通过，送外审（3名审稿人）<br>​​一审结果​​3个月，​​2人支持修订，1人拒稿​​<br>​​申诉2周，提供领域内权威文献证明K→R突变的普适性，编辑同意转大修<br>​​返修提交​​1个月多月<br>​​二审结果​​2个月，Reviewer 1/2无意见，Reviewer 3仍拒稿，编辑最终拒稿，太折腾了悲催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Mon Jun 09 23:23:33 CST 2025, time=2025-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2252190, encodeId=eb1e225219097, content=请问是否需要那个作者确认？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70d82534981, createdName=1250caacm11暂无昵称, createdTime=Sun Feb 16 14:42:55 CST 2025, time=2025-02-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2226589, encodeId=ee43222658985, content=请问一下Cell Rep跟JECCR，选哪一个好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c4c05433377, createdName=ms4000000962704650, createdTime=Thu Sep 19 15:39:00 CST 2024, time=2024-09-19, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=296, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2240785, encodeId=82a82240e85ca, content=即时影响因子5.83，为什么一直在降呢，上边的文章质量都很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Wed Dec 04 15:25:04 CST 2024, time=2024-12-04, status=1, ipAttribution=北京)]
    2024-09-19 ms4000000962704650 来自江西省

    请问一下Cell Rep跟JECCR，选哪一个好

    3

    展开3条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2214992, encodeId=23d1221499279, content=with editor都12天了都还没更新状态，正常不呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=280, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Mon Jul 15 10:10:53 CST 2024, time=2024-07-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278979, encodeId=b5c622e8979b4, content=送审后审稿人说图像可能有问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f158275089, createdName=ms9000000864190369, createdTime=Wed Aug 27 21:46:50 CST 2025, time=2025-08-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2268654, encodeId=fe9e22686547a, content=审稿严谨，但编辑倾向维护审稿人权威<br>​​投稿​​1周，编辑初审通过，送外审（3名审稿人）<br>​​一审结果​​3个月，​​2人支持修订，1人拒稿​​<br>​​申诉2周，提供领域内权威文献证明K→R突变的普适性，编辑同意转大修<br>​​返修提交​​1个月多月<br>​​二审结果​​2个月，Reviewer 1/2无意见，Reviewer 3仍拒稿，编辑最终拒稿，太折腾了悲催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Mon Jun 09 23:23:33 CST 2025, time=2025-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2252190, encodeId=eb1e225219097, content=请问是否需要那个作者确认？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70d82534981, createdName=1250caacm11暂无昵称, createdTime=Sun Feb 16 14:42:55 CST 2025, time=2025-02-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2226589, encodeId=ee43222658985, content=请问一下Cell Rep跟JECCR，选哪一个好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c4c05433377, createdName=ms4000000962704650, createdTime=Thu Sep 19 15:39:00 CST 2024, time=2024-09-19, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=296, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2240785, encodeId=82a82240e85ca, content=即时影响因子5.83，为什么一直在降呢，上边的文章质量都很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Wed Dec 04 15:25:04 CST 2024, time=2024-12-04, status=1, ipAttribution=北京)]
    2024-04-30 darktempler 来自江苏省

    说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！

    3

    展开3条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2214992, encodeId=23d1221499279, content=with editor都12天了都还没更新状态，正常不呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=280, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Mon Jul 15 10:10:53 CST 2024, time=2024-07-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278979, encodeId=b5c622e8979b4, content=送审后审稿人说图像可能有问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f158275089, createdName=ms9000000864190369, createdTime=Wed Aug 27 21:46:50 CST 2025, time=2025-08-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2268654, encodeId=fe9e22686547a, content=审稿严谨，但编辑倾向维护审稿人权威<br>​​投稿​​1周，编辑初审通过，送外审（3名审稿人）<br>​​一审结果​​3个月，​​2人支持修订，1人拒稿​​<br>​​申诉2周，提供领域内权威文献证明K→R突变的普适性，编辑同意转大修<br>​​返修提交​​1个月多月<br>​​二审结果​​2个月，Reviewer 1/2无意见，Reviewer 3仍拒稿，编辑最终拒稿，太折腾了悲催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Mon Jun 09 23:23:33 CST 2025, time=2025-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2252190, encodeId=eb1e225219097, content=请问是否需要那个作者确认？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70d82534981, createdName=1250caacm11暂无昵称, createdTime=Sun Feb 16 14:42:55 CST 2025, time=2025-02-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2226589, encodeId=ee43222658985, content=请问一下Cell Rep跟JECCR，选哪一个好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c4c05433377, createdName=ms4000000962704650, createdTime=Thu Sep 19 15:39:00 CST 2024, time=2024-09-19, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=296, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2240785, encodeId=82a82240e85ca, content=即时影响因子5.83，为什么一直在降呢，上边的文章质量都很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Wed Dec 04 15:25:04 CST 2024, time=2024-12-04, status=1, ipAttribution=北京)]
    2023-06-14 ms7000001335611101 来自天津

    偏重的研究方向：医学;肿瘤
    经验分享：请问under review是送审了吗？为什么没收到邮件呢

    3

    展开3条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2214992, encodeId=23d1221499279, content=with editor都12天了都还没更新状态，正常不呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=280, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Mon Jul 15 10:10:53 CST 2024, time=2024-07-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278979, encodeId=b5c622e8979b4, content=送审后审稿人说图像可能有问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f158275089, createdName=ms9000000864190369, createdTime=Wed Aug 27 21:46:50 CST 2025, time=2025-08-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2268654, encodeId=fe9e22686547a, content=审稿严谨，但编辑倾向维护审稿人权威<br>​​投稿​​1周，编辑初审通过，送外审（3名审稿人）<br>​​一审结果​​3个月，​​2人支持修订，1人拒稿​​<br>​​申诉2周，提供领域内权威文献证明K→R突变的普适性，编辑同意转大修<br>​​返修提交​​1个月多月<br>​​二审结果​​2个月，Reviewer 1/2无意见，Reviewer 3仍拒稿，编辑最终拒稿，太折腾了悲催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Mon Jun 09 23:23:33 CST 2025, time=2025-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2252190, encodeId=eb1e225219097, content=请问是否需要那个作者确认？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70d82534981, createdName=1250caacm11暂无昵称, createdTime=Sun Feb 16 14:42:55 CST 2025, time=2025-02-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2226589, encodeId=ee43222658985, content=请问一下Cell Rep跟JECCR，选哪一个好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c4c05433377, createdName=ms4000000962704650, createdTime=Thu Sep 19 15:39:00 CST 2024, time=2024-09-19, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=296, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2240785, encodeId=82a82240e85ca, content=即时影响因子5.83，为什么一直在降呢，上边的文章质量都很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Wed Dec 04 15:25:04 CST 2024, time=2024-12-04, status=1, ipAttribution=北京)]
    2023-06-14 ms7000001335611101 来自天津

    偏重的研究方向：医学;肿瘤
    经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2214992, encodeId=23d1221499279, content=with editor都12天了都还没更新状态，正常不呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=280, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Mon Jul 15 10:10:53 CST 2024, time=2024-07-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=581662, encodeId=901c581662e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享：allreviewcompleted等待编辑决定煎熬中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211203/759b1de1e9b74beaa541e189f550ed91/477fced93abb4000bd738eeeb8ff850c.jpg, createdBy=3b085248437, createdName=147d7137m03(暂无昵称), createdTime=Tue Dec 17 15:38:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278979, encodeId=b5c622e8979b4, content=送审后审稿人说图像可能有问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f158275089, createdName=ms9000000864190369, createdTime=Wed Aug 27 21:46:50 CST 2025, time=2025-08-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2268654, encodeId=fe9e22686547a, content=审稿严谨，但编辑倾向维护审稿人权威<br>​​投稿​​1周，编辑初审通过，送外审（3名审稿人）<br>​​一审结果​​3个月，​​2人支持修订，1人拒稿​​<br>​​申诉2周，提供领域内权威文献证明K→R突变的普适性，编辑同意转大修<br>​​返修提交​​1个月多月<br>​​二审结果​​2个月，Reviewer 1/2无意见，Reviewer 3仍拒稿，编辑最终拒稿，太折腾了悲催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Mon Jun 09 23:23:33 CST 2025, time=2025-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2252190, encodeId=eb1e225219097, content=请问是否需要那个作者确认？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70d82534981, createdName=1250caacm11暂无昵称, createdTime=Sun Feb 16 14:42:55 CST 2025, time=2025-02-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2226589, encodeId=ee43222658985, content=请问一下Cell Rep跟JECCR，选哪一个好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c4c05433377, createdName=ms4000000962704650, createdTime=Thu Sep 19 15:39:00 CST 2024, time=2024-09-19, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=296, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤<br>经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2240785, encodeId=82a82240e85ca, content=即时影响因子5.83，为什么一直在降呢，上边的文章质量都很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Wed Dec 04 15:25:04 CST 2024, time=2024-12-04, status=1, ipAttribution=北京)]
    2024-12-04 147f2cd9m92暂无昵称 来自北京

    即时影响因子5.83，为什么一直在降呢，上边的文章质量都很好

    2

    展开2条回复
共391条页码: 1/40页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分